Novartis AG (NOVN) named Dirk Kosche as the head of its Japan business today, replacing Yoshiyasu Ninomiya after investigations showed that the unit involved itself in drug studies that were supposed to be independent of the company.
Novartis needs to rebuild a company in Japan that meets “legal obligations and executes operations ethically” under new management, the Basel, Switzerland-based drugmaker’s Japanese unit said in a statement today.
